Spotlight on cetuximab in squamous cell carcinoma of the head and necky
JE Frampton - BioDrugs, 2011 - Springer
Cetuximab (Erbitux®) is a chimeric monoclonal antibody directed against the human
epidermal growth factor receptor (EGFR). EGFR is overexpressed and/or upregulated in …
epidermal growth factor receptor (EGFR). EGFR is overexpressed and/or upregulated in …
Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck
F Perri, F Longo, F Ionna, F Caponigro - OncoTargets and therapy, 2009 - Taylor & Francis
Cetuximab is a chimeric monoclonal antibody that targets the epidermal growth factor
receptor. The role of cetuximab is paramount in several subsets of head and neck cancer. In …
receptor. The role of cetuximab is paramount in several subsets of head and neck cancer. In …
Cetuximab in the treatment of head and neck cancer
J Bernier - Expert review of anticancer therapy, 2006 - Taylor & Francis
Approaches to the treatment of locally advanced and recurrent and/or metastatic squamous
cell carcinoma of the head and neck (SCCHN) have been limited by their toxicity. Effective …
cell carcinoma of the head and neck (SCCHN) have been limited by their toxicity. Effective …
The role of cetuximab in the treatment of squamous cell cancer of the head and neck
B Burtness - Expert opinion on biological therapy, 2005 - Taylor & Francis
The epidermal growth factor receptor (EGFR) is a member of the HER family of tyrosine
kinase growth factor receptors. Binding to EGFR by its natural ligands, mainly epidermal …
kinase growth factor receptors. Binding to EGFR by its natural ligands, mainly epidermal …
Cetuximab as off-label monotherapy for advanced head and neck squamous cell carcinoma
PQ Tran, J Park, IMC Seuthe - Laryngo-Rhino-Otologie, 2024 - thieme-connect.com
Discussion The present case shows the response of cetuximab in an auditory canal
squamous cell carcinoma in the palliative situation. The monoclonal antibody cetuximab …
squamous cell carcinoma in the palliative situation. The monoclonal antibody cetuximab …
Phase I study of cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in patients (pts) with recurrent and/or metastatic squamous cell …
Y Humblet, E Vega-Villegas, R Mesia… - Journal of Clinical …, 2004 - ascopubs.org
5513 Background: The goal of this study was to investigate the safety and efficacy of
cetuximab (Erbitux), an IgG1 monoclonal antibody targeting the EGFR, given in combination …
cetuximab (Erbitux), an IgG1 monoclonal antibody targeting the EGFR, given in combination …
Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck
M Merlano, M Occelli - Therapeutics and clinical risk management, 2007 - Taylor & Francis
Cetuximab is a monoclonal antibody able to inhibit and to degrade the transmembrane
receptor Her-1, also known as epidermal growth factor receptor (EGFR). The inhibition of …
receptor Her-1, also known as epidermal growth factor receptor (EGFR). The inhibition of …
[HTML][HTML] Cetuximab plus radiotherapy in patients with unresectable locally advanced squamous cell carcinoma of head and neck region-A open labelled single arm …
S Dattatreya, C Goswami - Indian Journal of Cancer, 2011 - journals.lww.com
Purpose: To evaluate feasibility, safety and outcome of cetuximab concurrent with
radiotherapy in locally advanced head− neck cancer. Materials and Methods: Between …
radiotherapy in locally advanced head− neck cancer. Materials and Methods: Between …
[PDF][PDF] The role of cetuximab in the treatment of head and neck cancer
P Specenier, J Vermorken - Belgian journal of medical oncology …, 2008 - academia.edu
As EGFR is overexpressed in over 90% of all squamous cell cancers of the head and neck
(SCCHN) there is a strong rationale supporting Epidermal Growth Factor Receptor (EGFR) …
(SCCHN) there is a strong rationale supporting Epidermal Growth Factor Receptor (EGFR) …